1-4 of 4
Andrew D. Weinberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A186: A new strategy to identify and expand tumor-reactive CD8 TILs in human solid tumors

Thomas Duhen, Rebekka Duhen, Ryan Montler, Tarsem Moudgil, Jitske van den Bulk, Bernard A. Fox, Shu-Ching Chang, Gary Grunkemeier, Els M.E. Verdegaal, Noel F. de Miranda, Rom Leidner, Richard B. Bell, Andrew D. Weinberg
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2_Supplement): A186.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A186
Published: 01 February 2019
View article titled, Abstract A186: A new strategy to identify and expand tumor-reactive CD8 TILs in human solid tumors
Journal Articles

Abstract B094: Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development

Jitske van den Bulk, Dina Ruano, Marieke E. Ijsselsteijn, Marten Visser, Ruud van der Breggen, Koen C.M.J. Peeters, Thomas Duhen, Rebekka Duhen, Andrew D Weinberg, Sjoerd S.H. van der Burg, Els M.E. Verdegaal, Noel F. de Miranda
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2_Supplement): B094.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B094
Published: 01 February 2019
View article titled, Abstract B094: Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development
Journal Articles

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist

Fanny Polesso, Andrew D. Weinberg, Amy E. Moran
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2): 269–281.
https://doi.org/10.1158/2326-6066.CIR-18-0222
Published: 01 February 2019
View article titled, Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist
Open the PDF for Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist in another window
Includes: Supplementary data
Journal Articles

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade

Todd A. Triplett, Christopher G. Tucker, Kendra C. Triplett, Zefora Alderman, Lihong Sun, Leona E. Ling, Emmanuel T. Akporiaye, Andrew D. Weinberg
Journal: Cancer Immunology Research
Series: Author Choice
Cancer Immunol Res (2015) 3 (5): 526–535.
https://doi.org/10.1158/2326-6066.CIR-14-0187
Published: 03 May 2015
View article titled, STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade
Open the PDF for STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade in another window